Advances and future perspectives in the treatment of small cell lung cancer: From chemotherapy and radiotherapy to the era of targeted therapy and immunotherapy.
Small cell lung cancer (SCLC) is an aggressive malignant tumor that mainly originates from pulmonary neuroendocrine cells and is characterized by rapid proliferation, high metastatic potential, and acquired therapeutic resistance. The therapeutic landscape for SCLC is largely confined to traditional modalities, such as surgery and chemoradiotherapy.
Small cell lung cancer (SCLC) is an aggressive malignant tumor that mainly originates from pulmonary neuroendocrine cells and is characterized by rapid proliferation, high metastatic potential, and acquired therapeutic resistance. The therapeutic landscape for SCLC is largely confined to traditional modalities, such as surgery and chemoradiotherapy.
What the study was
- Study design
- Journal Article (unspecified)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Cancer Res Ther
Why it surfaced
Matched watchlist topic 'Novel therapeutics: immunotherapy, CAR-T, targeted therapy'. Study design: Journal Article (unspecified). Score: 9/10 (N:3, R:3, D:1, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.